Check out this morning's top movers from around Wall Street, compiled by The Fly. 

HIGHER -

• Fly Leasing (FLY) up 26% after announcing that it has entered into a definitive agreement to be acquired by an affiliate of Carlyle Aviation Partners (CG)
• Humanigen (HGEN) up 59% after announcing topline results from its Phase 3 clinical trial evaluating lenzilumab in patients hospitalized with COVID-19, showing that patients who received lenzilumab and other treatments had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments
• Bluebird Bio (BLUE) up 6% after Bristol Myers Squibb (BMY) and the company announced that the FDA has approved Abecma as the first B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy
• Tencent Music (TME) up 5% after announcing that its board of directors has authorized a share repurchase program under which the company may repurchase up to $1B of its Class A ordinary shares
• Twitter (TWTR) up 2% after Truist analyst Youssef Squali upgraded shares to Buy from Hold with a price target of $74, up from $64

• Credit Suisse (CS) and Nomura (NMR) both down 13% in New York pre-market trading after the companies reported that a hedge fund default could bring them significant Q1 losses
• Orphazyme (ORPH) down 31% after announcing its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis did not meet its primary and secondary endpoints
• Adecoagro (AGRO) down 3% after Morgan Stanley analyst Javier Martinez de Olcoz downgraded the stock to Equal Weight from Overweight